Nuwellis Regains Compliance with Nasdaq Listing Requirements

Rhea-AI Summary

Nuwellis (Nasdaq: NUWE), a medical technology company specializing in fluid management solutions, has successfully regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). The company received formal confirmation from Nasdaq on July 22, 2025, resolving their previously disclosed bid price deficiency.

As a result, the scheduled hearing with the Nasdaq Hearings Panel for August 12, 2025, has been cancelled, and Nuwellis' common stock will continue trading on the Nasdaq Capital Market under the ticker "NUWE".

Positive

• Regained compliance with Nasdaq listing requirements
• Maintains Nasdaq Capital Market listing status
• Avoided potential delisting proceedings

Negative

• Previous bid price deficiency indicates recent stock price weakness

MINNEAPOLIS, July 23, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on fluid management solutions for patients with fluid overload, today announced that it has regained compliance with the Nasdaq Capital Market’s minimum bid price requirement under Listing Rule 5550(a)(2).

On July 22, 2025, the Company received formal notice from Nasdaq stating that it has resolved the previously disclosed bid price deficiency. As a result, the hearing previously scheduled with the Nasdaq Hearings Panel for August 12, 2025, has been cancelled, and shares of the Company’s common stock will continue to be listed and traded on the Nasdaq Capital Market under the ticker “NUWE.”

For more information, visit www.nuwellis.com.

About Nuwellis Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow^® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn or X, formerly known as Twitter.

About the Aquadex SmartFlow^® System The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2025 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.

For further information, please contact:

Investor Relations:
Robert Scott
Chief Financial Officer
ir@nuwellis.com

Media Contact:
Leah McMullen
Director of Communications
Leah.mcmullen@nuwellis.com

FAQ

Has Nuwellis (NUWE) resolved its Nasdaq listing compliance issues?

Yes, on July 22, 2025, Nuwellis received formal notice from Nasdaq confirming it has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2).

Will Nuwellis (NUWE) continue trading on Nasdaq?

Yes, Nuwellis shares will continue to be listed and traded on the Nasdaq Capital Market under the ticker 'NUWE' as the company has resolved its bid price deficiency.

What was the scheduled Nasdaq hearing date for Nuwellis (NUWE)?

A hearing was scheduled with the Nasdaq Hearings Panel for August 12, 2025, but has been cancelled due to the company regaining compliance.

What does Nuwellis (NUWE) do as a company?

Nuwellis is a medical technology company that focuses on developing fluid management solutions for patients with fluid overload.